GLP-1 brand guide
Compare GLP-1 brands: Wegovy, Ozempic, Zepbound and Mounjaro
Wegovy and Ozempic are both semaglutide. Zepbound and Mounjaro are both tirzepatide. The drug inside each pair is the same. The drug may be the same, but the product is not: approved use, dose schedule, age range and device can all change.
Source: Read from the four current FDA labels on DailyMed, 2026-08-12
What matters first
Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-12
What is each brand approved to treat?
Every row below is one thing an FDA label says a product is approved to do. A dash means that label does not cover it, which is a fact about the product rather than a gap in our table.
| Approved use | WegovySemaglutide | OzempicSemaglutide | ZepboundTirzepatide | MounjaroTirzepatide | TrulicityDulaglutide | VictozaLiraglutide | SaxendaLiraglutide | RybelsusSemaglutide |
|---|---|---|---|---|---|---|---|---|
| Weight reduction in adults | Yes | — | Yes | — | — | — | Yes | — |
| Weight reduction from age 12 | Yes | — | — | — | — | — | Yes | — |
| Blood sugar in adults with type 2 diabetes | — | Yes | — | Yes | Yes | Yes | — | Yes |
| Blood sugar from age 10 | — | — | — | Yes | Yes | Yes | — | — |
| Heart risk, with obesity or overweight | Yes | — | — | — | — | — | — | — |
| Heart risk, with type 2 diabetes | — | Yes | — | — | Yes | Yes | — | Yes |
| Kidney decline in type 2 diabetes | — | Yes | — | — | — | — | — | — |
| Obstructive sleep apnea | — | — | Yes | — | — | — | — | — |
| Noncirrhotic MASH with liver fibrosis | Yes | — | — | — | — | — | — | — |
Where does each dose schedule stop?
This is the number most people are looking for, and it is the one that splits each pair apart hardest.
| Brand | Starts at | Tops out at | Steps on the way | Youngest covered |
|---|---|---|---|---|
| Wegovy | 0.25 mg | 7.2 mg | 6 | Age 12 |
| Ozempic | 0.25 mg | 2 mg | 4 | Adults only |
| Zepbound | 2.5 mg | 15 mg | 6 | Adults only |
| Mounjaro | 2.5 mg | 15 mg | 6 | Age 10 |
| Trulicity | 0.75 mg | 4.5 mg | 4 | Age 10 |
| Victoza | 0.6 mg | 1.8 mg | 3 | Age 10 |
| Saxenda | 0.6 mg | 3 mg | 5 | Age 12 |
| Rybelsus | 3 mg | 14 mg | 3 | Adults only |
Which brands share a drug?
Two pairs, and each pair has one thing worth knowing before you assume the pages are interchangeable.
Which two would you actually be choosing between?
Three pairs get asked about far more than the rest. Each has one page, and both ways of phrasing the question land on it.
- Mounjaro against Ozempic, line by line — two drugs, one job, and one head-to-head trial.
- Wegovy against Ozempic, line by line — one drug substance, two labels.
- Mounjaro against Zepbound, line by line — one drug substance, two labels.
- Zepbound against Ozempic, line by line — two drugs, one job, and one head-to-head trial.
- Wegovy against Mounjaro, line by line — two drugs, one job, and one head-to-head trial.
What do the drug pages cover instead?
These brand pages stay on the label: who it covers, what schedule it prints, what device it comes in. The drug pages answer the other half.
- The semaglutide dosage chart covers the drug itself, including vial and syringe arithmetic no brand pen needs.
- The tirzepatide dosage chart does the same for the drug in Zepbound and Mounjaro.
- Wegovy against Zepbound, side by side is the head-to-head, and it is the only pair here with a randomized trial behind it.
- What all four cost, and who each price is for answers the money question these label pages deliberately leave alone.
Questions readers ask
What is the best brand of GLP-1?
Is Zepbound better than Ozempic?
What are the top 10 GLP-1 drugs?
Which GLP-1 provider is the best?
- Wegovy (semaglutide) injection and tablets — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-12FDA label
- Wegovy (semaglutide) Prescribing Information, revised 06/2026 — Drugs@FDA NDA 215256/S-025retrieved 2026-08-12FDA label
- FDA approval letter, NDA 215256 — Wegovy (semaglutide) injection, chronic weight management in adultsretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215256/S-005 — Wegovy in pediatric patients aged 12 years and olderretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215256/S-011 — Wegovy cardiovascular risk reduction indication (SELECT)retrieved 2026-08-12FDA label
- FDA accelerated approval letter, NDA 215256/S-024 — Wegovy for noncirrhotic MASH with stage F2 to F3 fibrosisretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215256/S-029 — Wegovy injection 7.2 mg once-weekly doseretrieved 2026-08-12FDA label
- FDA approval letter, NDA 218316 — Wegovy (semaglutide) tablets, oral dosage formretrieved 2026-08-12FDA label
- Ozempic (semaglutide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-12FDA label
- Drugs@FDA approval history — NDA 209637, Ozempic (semaglutide) injectionretrieved 2026-08-12FDA label
- FDA approval letter, NDA 209637 — Ozempic (semaglutide) injection, glycemic control in adults with type 2 diabetesretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 209637/S-003 — Ozempic cardiovascular event risk reduction in type 2 diabetes with established cardiovascular disease (SUSTAIN 6)retrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 209637/S-025 — Ozempic for reducing sustained eGFR decline, end-stage kidney disease and cardiovascular death in type 2 diabetes with chronic kidney diseaseretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 209637/S-009 — addition of a third Ozempic maintenance dose, 2 mg once weeklyretrieved 2026-08-12FDA label
- Zepbound (tirzepatide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-12FDA label
- Zepbound (tirzepatide) Prescribing Information, revised 02/2026 — Drugs@FDA NDA 217806/S-042retrieved 2026-08-12FDA label
- FDA approval letter, NDA 217806 — Zepbound (tirzepatide) injection, chronic weight management in adultsretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 217806/S-013 — Zepbound for moderate to severe obstructive sleep apnearetrieved 2026-08-12FDA label
- Mounjaro (tirzepatide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-12FDA label
- Drugs@FDA approval history — NDA 215866, Mounjaro (tirzepatide) injectionretrieved 2026-08-12FDA label
- FDA approval letter, NDA 215866 — Mounjaro (tirzepatide) injection, glycemic control in adults with type 2 diabetesretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215866/S-039 — expansion of the Mounjaro type 2 diabetes indication to pediatric patients aged 10 years and older (trial I8F-MC-GPGV)retrieved 2026-08-12FDA label
- Trulicity (dulaglutide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-13FDA label
- Trulicity (dulaglutide) Prescribing Information, revised 03/2026 — Drugs@FDA BLA 125469/S-065retrieved 2026-08-13FDA label
- FDA licensing letter, BLA 125469 — Trulicity (dulaglutide), glycemic control in adults with type 2 diabetesretrieved 2026-08-13FDA label
- FDA supplement approval letter, BLA 125469/S-051 — expansion of the Trulicity glycemic-control indication to pediatric patients 10 years of age and olderretrieved 2026-08-13FDA label
- FDA supplement approval letter, BLA 125469/S-033 — Trulicity indication for reducing major adverse cardiovascular events in type 2 diabetes (REWIND)retrieved 2026-08-13FDA label
- Drugs@FDA via openFDA — every application containing dulaglutide, which is BLA 125469 and nothing elseretrieved 2026-08-13FDA label
- Victoza (liraglutide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-13FDA label
- Victoza (liraglutide) Prescribing Information, revised 10/2025 — Drugs@FDA NDA 022341/S-046retrieved 2026-08-13FDA label
- FDA approval letter, NDA 022341 — Victoza (liraglutide) injection, glycemic control in adults with type 2 diabetesretrieved 2026-08-13FDA label
- FDA supplement approval letter, NDA 022341/S-031 — expansion of the Victoza type 2 diabetes age range to patients 10 years and older (ELLIPSE)retrieved 2026-08-13FDA label
- FDA supplement approval letter, NDA 022341/S-027 — Victoza indication for reducing major adverse cardiovascular events in type 2 diabetes with established cardiovascular disease (LEADER)retrieved 2026-08-13FDA label
- Drugs@FDA via openFDA — applications containing liraglutide, including the approved abbreviated new drug applications from Sandoz, Teva, Lupin, Hikma, Biocon, Mylan, Fresenius Kabi and others, and the label each one carriesretrieved 2026-08-13FDA label
- Saxenda (liraglutide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-13FDA label
- Saxenda (liraglutide) Prescribing Information, revised 02/2026 — Drugs@FDA NDA 206321/S-025retrieved 2026-08-13FDA label
- FDA approval letter, NDA 206321 — Saxenda (liraglutide) injection, chronic weight management in adultsretrieved 2026-08-13FDA label
- FDA supplement approval letter, NDA 206321/S-012 — addition of a Saxenda pediatric indication for ages 12 and older (trial NN8022-4180)retrieved 2026-08-13FDA label
- Rybelsus and Ozempic (semaglutide) tablets — one FDA-approved Prescribing Information covering both names (DailyMed)retrieved 2026-08-20FDA label
- Rybelsus (semaglutide) tablets Prescribing Information, revised 01/2026 — Drugs@FDA NDA 213051/S-030retrieved 2026-08-13FDA label
- FDA approval letter, NDA 213051 — Rybelsus (semaglutide) tablets, glycemic control in adults with type 2 diabetesretrieved 2026-08-13FDA label
- FDA supplement approval letter, NDA 213051/S-024 — Rybelsus indication for reducing major adverse cardiovascular events in adults with type 2 diabetes at high riskretrieved 2026-08-13FDA label
- FDA drug shortages database via openFDA — Rybelsus 3 mg, 7 mg and 14 mg tablets, status To Be Discontinued, to be replaced by Ozempic tabletsretrieved 2026-08-13FDA label